Highbridge Capital Management LLC Biogen Inc. Transaction History

Highbridge Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $2.09 Million - $2.64 Million	-7,491 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $13.7 Million - $18 Million	-46,819 Reduced 86.21%	7,491 $2.65 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $13.7 Million - $19.4 Million	52,710 Added 3294.38%	54,310 $14.9 Million
Q4 2017 Feb 14, 2018	SELL	$307.64 - $344.58 $17.4 Million - $19.4 Million	-56,407 Reduced 97.24%	1,600 $510,000
Q2 2017 Aug 14, 2017	BUY	N/A	58,007	58,007 $15.7 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Highbridge Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Highbridge Capital Management LLC with notifications on news.